Positive outcomes for iSTAR Medical’s MIGS MINIject shown in trials of over 130 glaucoma patients

Pooled data confirm excellent safety and efficacy profile with very low rate of reintervention WAVRE, Belgium — 29 September 2020: iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma, announced today that its micro-invasive glaucoma surgery (MIGS) device MINIjectTM showed consistently positive safety and efficacy […]

Journal of Glaucoma published MINIject six-month clinical data

Successful primary endpoint results of MINIject in the European clinical trial STAR-II have been published in the peer-reviewed Journal of Glaucoma. The data confirm that MINIject met the study primary endpoints with over 75 percent of patients reaching prospectively defined success. In the trial, mean intraocular pressure (IOP) was reduced by 40 percent to 14.7 […]

iSTAR Medical nominated for BVA Award

iSTAR Medical has been selected as one of three nominees for the 2020 BVA Award “Venture company of the year”. The Award is organised by the Belgian Venture Capital & Private Equity Association to reward and celebrate high-performing Belgian companies backed by private equity or venture capital funds.

First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma

Two-year final results from STAR-I trial and initial data from STAR-II European trial tout MINIjectTM as a highly promising treatment. WAVRE, Belgium — 29 April 2020: iSTAR Medical SA, a clinical-stage medical device company pioneering truly biocompatible solutions for glaucoma, today announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant […]

iSTAR Medical announces EUR 40m Series C Financing

To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM WAVRE, Belgium — 5 September 2019:  iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced the completion of a €40m Series C financing. The financing was led by healthcare specialist funds LSP and Gimv, with participation […]